BRight Pharmacokinetic Study

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

June 27, 2024

Study Completion Date

July 22, 2025

Conditions
Peripheral Artery Disease
Interventions
DEVICE

BRight DCB

The BRight Drug-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon catheter (BRight DCB) is intended for dilatation of de novo lesions in native superficial femoral or popliteal arteries with a simultaneous release of drug to the vessel wall as a secondary action to reduce occurrence of a restenosis of the treated vessel segment.

Trial Locations (1)

Unknown

Royal Perth Hospital, Perth

All Listed Sponsors
lead

Biotronik CRC Inc.

INDUSTRY

NCT06065345 - BRight Pharmacokinetic Study | Biotech Hunter | Biotech Hunter